Investigation of the binding determinants of phosphopeptides targeted to the Src homology 2 domain of the signal transducer and activator of transcription 3. Development of a high-affinity peptide inhibitor

Journal of Medicinal Chemistry

Volumn 48, Issue 21, 2005, Pages 6661-6670

  Coleman IV, David R ^a,b   Ren, Zhiyong ^a,b   Mandal, Pijus K ^a   Cameron, Arlin G ^a   Dyer, Garrett A ^a   Muranjan, Seema ^a   Campbell, Martin ^a   Chen, Xiaomin ^a   McMurray, John S ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BENZYL DERIVATIVE; DIPEPTIDE; GLUTAMINE; LEUCINE; METHANOPROLINE; METHYL GROUP; PHOSPHOPEPTIDE; PROLINE DERIVATIVE; PROTEIN INHIBITOR; PROTEIN TYROSINE KINASE; STAT3 PROTEIN; SYNTHETIC PEPTIDE; TETRAPEPTIDE; THREONYLVALINE; UNCLASSIFIED DRUG;

AMINO ACID SUBSTITUTION; AMINO TERMINAL SEQUENCE; ARTICLE; BINDING AFFINITY; DIMERIZATION; FLUORESCENCE POLARIZATION; HYDROGEN BOND; HYDROPHOBICITY; LIPOPHILICITY; METHYLATION; PEPTIDE SYNTHESIS; PROTEIN BINDING; PROTEIN DNA BINDING; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION; SOLID PHASE SYNTHESIS; SRC HOMOLOGY DOMAIN; STRUCTURE ACTIVITY RELATION;

EID: 27144475507     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm050513m     Document Type: Article

References (76)

1. (a) Bromberg, J.; Darnell, J. E., Jr. The role of STATs in transcriptional control and their impact on cellular function. Oncogens 2000, 19, 2468-2473.
2. (b) Levy, D. E.; Darnell, J. E., Jr. Stats: transcriptional control and biological impact. Nat. Rev. Mol. Cell Biol. 2002, 3, 651-662.
3. (c) Stark, G. R.; Kerr, I. M.; Williams, B. R.; Silverman, R. H.; Schreiber, R. D. How cells respond to interferons. Annu. Rev. Biochem. 1998, 67, 227-264.
4. Akira, S.; Nishio, Y.; Inoue, M.; Wang, X. J.; Wei, S.; Matsusaka, T.; Yoshida, K.; Sudo, T.; Naruto, M.; Kishimoto, T. Molecular cloning of APRF, a novel IFN-stimulated gene factor 3 p91-related transcription factor involved in the gp130-mediated signaling pathway. Cell 1994, 77, 63-71.
5. (a) Zhong, Z.; Wen, Z.; Darnell, J. E., Jr. Stat3: A STAT family member activated by tyrosine phosphorylation in response to epidermal growth factor and interleukin-6. Science 1994, 264, 95-98.
6. (b) Zhong, Z.; Wen, Z.; Darnell, J. E., Jr. Stat3 and Stat4: Members of the Family of signal transducers and activators of transcription. Proc. Nat. Acad. Sci. U.S.A. 1994, 91, 4806-4810.
7. Stahl, N.; Farruggella, T. J.; Boulton, T. G.; Zhong, Z.; Darnell, J. E.; Yancopoulos, G. D. Choice of STATs and other substrates specified by modular tyrosine-based motifs in cytokine receptors. Science 1995, 267, 1349-1353.
8. Gerhartz, C.; Heesel, B.; Sasse, J.; Hemmann, U.; Landgraf, C.; Schneider-Mergener, J.; Horn, F.; Heinrich, P. C.; Graeve, L. Differential activation of acute phase response factor/STAT3 and STAT1 via the cytoplasmic domain of the interleukin 6 signal transducer gp 130. I. Definition of a novel phosphotyrosine motif mediating STAT1 activation. J. Biol. Chem. 1996, 271, 12991-12998.
9. (a) Coffer, P.; Kruijer, W. EGF receptor deletions define a region specifically mediating STAT transcription factor activation. Biochem. Biophys. Res. Commun. 1995, 210, 74-81.
10. (b) Tong, Z.; Jing, M.; Xinmin, C. Grb2 regulates Stat3 activation negatively in epidermal growth factor signalling. Biochem. J. 2003, 376, 457-464.
11. Schreiner, S. J.; Schiavone, A. P.; Smithgall, T. E. Activation of STAT3 by the Src family kinase Hck requires a functional SH3 domain. J. Biol. Chem. 2002, 277, 45680-45687.
12. Song, J, I.; Grandis, J. R. STAT signaling in head and neck cancer. Oncogene 2000, 19, 2489-2495.
13. Garcia, R.; Yu, C. L.; Hudnall, A.; Catlett, R.; Nelson, K. L.; Smithgall, T.; Fujita, D. J.; Ethier, S. P.; Jove, R. Constitutive activation of Stat3 in fibroblasts transformed by diverse oncoproteins and in breast carcinoma cells. Cell Growth Differ. 1997, 872, 1267-1276.
14. Schaefer, L. K.; Ren, Z.; Fuller, G. N.; Schaefer, T. S. Constitutive activation of Stat3a in brain tumors: localization to tumor endothelial cells and activation by the endothelial tyrosine kinase receptor (VEGFR-2). Oncogene 2002, 21, 2058-2065.
15. Dhir, R.; Ni, Z.; Lou, W.; DeMiguel, F.; Grandis, J. R.; Gao, A. C. Stat3 activation in prostatic carcinomas. Prostate 2002, 51, 241-246.
16. Seki, Y.; Suzuki, N.; Imaizumi, M.; Iwamoto, T.; Usami, N.; Ueda, Y.; Hamaguchi, M. STAT3 and MAPK in human lung cancer tissues and suppression of oncogenic growth by JAB and dominant negative STAT3. Int. J. Oncol 2004, 24, 931-934.
17. Benekli, M.; Baer, M. R.; Baumann, H.; Wetzler, M. Signal transducer and activator of transcription proteins in leukemias. Blood 2003, 101, 2940-2954.
18. Catlett-Falcone, R.; Landowski, T. H.; Oshiro, M. M.; Turkson, J.; Levitzki, A.; Savino, R.; Ciliberto, G.; Moscinski, L.; Fernandez-Luna, J. L.; Nunez, G.; Dalton, W. S.; Jove, R. Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity 1999, 101, 105-115.
19. Weber-Nordt, R. M.; Egen, C.; Wehinger, J.; Ludwig, W.; Gouilleux-Gruart, V.; Mertelsmann, R.; Finke, J. Constitutive activation of STAT proteins in primary lymphoid and myeloid leukemia cells and in Epstein-Barr virus (EBV)-related lymphoma cell lines. Blood 1996, 88, 809-816.
20. Scholz, A.; Heinze, S.; Detjen, K. M.; Peters, M.; Welzel, M.; Hauff, P.; Schirner, M.; Wiedenmann, B.; Rosewicz, S. Activated signal transducer and activator of transcription 3 (STAT3) supports the malignant phenotype of human pancreatic cancer. Gastroenterology 2003, 125, 891-905.
21. (a) Bowman, T.; Garcia, R.; Turkson, J.; Jove, R. STATs in oncogenesis. Oncogene 2000, 19, 2474-2488.
22. (b) Buettner, R.; Mora, L. B.; Jove, R. Activated STAT signaling in human tumors provides novel molecular targets for therapeutic intervention. Clin. Cancer Res. 2002, 8, 945-954.
23. (c) Bromberg, J. Stat proteins and oncogenesis. J. Clin. Invest. 2002, 109, 1139-1142.
24. (d) Darnell, J. E., Jr. Transcription factors as targets for cancer therapy. Nat. Rev. Cancer 2002, 2, 740-749.
25. (e) Yu, H.; Jove, R. The STAT3 of cancer. New molecular targets come of age. Nat. Rev. Cancer 2004, 4, 97-105.
26. (a) Burke, W. M.; Jin, X.; Lin, H.-J.; Huang, M.; Liu, R.; Reynolds, R. K.; Lin, J. Inhibition of constitutively active Stat3 suppresses growth of human ovarian and breast cancer cells. Oncogene 2001, 20, 7925-7934.
27. (b) Niu, G.; Heller, R.; Catlett-Falcone, R.; Coppola, D.; Jaroszeski, M.; Dalton, W.; Jove, R.; Yu, H. Gene therapy with dominant-negative Stat3 suppresses growth of the murine melanoma B16 tumor in vivo. Cancer Res. 1999, 59, 5059-5063.
28. (c) Grandis, J. R.; Drenning, S. D.; Chakraborty, A.; Zhou, M.-Y.; Zeng, Q.; Pitt, A. S.; Tweardy, D. J. Requirement of Stat3 but not Stat1 activation for epidermal growth factor receptor-mediated cell growth in vitro. J. Clin. Invest. 1998, 102, 1385-1392.
29. (d) Grandis, J. R.; Drenning, S. D.; Zeng, Q.; Watkins, S. C.; Melhem, M. F.; Endo, S.; Johnson, D. E.; Huang, L.; He, Y.; Kim, J. D. Constitutive activation of Stat3 signaling abrogates apoptosis in squamous cell carcinogenesis in vivo Proc. Natl. Acad. Sci. U.S.A. 2000, 97, 4227-4232.
30. Real, P. J.; Sierra, A.; de Juan, A.; Segovia, J. C.; Lopez-Vega, J. M.; Fernandez-Luna, J. L. Resistance to chemotherapy via Stat3-dependent overexpression of Bcl-2 in metastatic breast cancer cells. Oncogene 2002, 21, 7611-7618.
31. Garcia, R.; Bowman, T. L.; Niu, G.; Yu, H.; Minton, S.; Muro-Cacho, C. A.; Cox, C. E.; Falcone, R.; Fairclough, R.; Parsons, S.; Laudano, A.; Gazit, A.; Levitzki, A.; Kraker, A.; Jove, R. Constitutive activation of Stat3 by the Src and JAK tyrosine kinases participates in growth regulation of human breast carcinoma cells. Oncogene 2001, 20, 249-2513.
32. (a) Sawyer, T. K. Src homology-2 domains: structure, mechanisms, and drug discovery. Biopolymers 1998, 47, 243-261.
33. (b) Cody, W. L.; Lin, Z.; Panek, R. L.; Rose, D. W.; Rubin, J. R. Progress in the development of inhibitors of SH2 domains. Curr. Pharm. Des. 2000, 6, 59-98.
34. (c) Muller, G. Peptidomimetic SH2 domain antagonists for targeting signal transduction. Top. Curr. Chem. 2001, 211, 17-59.
35. (d) Shakespeare, W. C. SH2 domain inhibition: a problem solved? Curr. Opin. Chem. Biol. 2001, 5, 409-415.
36. (e) Metcalf, C. A., III; Sawyer, T. Src Homology-2 Domains and Structure-based, Small-molecule Library Approaches to Drug Discovery. In Drug Discovery Strategies and Methods; Makriyannis, A., Biegel, D., Eds.; Marcel Dekker: New York, 2004; pp 23-59.
37. Pawson, T. Protein modules and signalling networks. Nature 1995, 373, 573-580.
38. (a) Songyang, Z.; Shoelson, S. E.; Chaudhuri, M.; Gish, G.; Pawson, T.; Haser, W. G.; King, F.; Roberts, T.; Ratnofsky, S.; Lechleider, R. J. SH2 domains recognize specific phosphopeptide sequences. Cell 1993 72, 767-778.
39. (b) Songyang, Z.; Shoelson, S. E.; McGlade, J.; Olivier, P.; Pawson, T.; Bustelo, X. R.; Barbacid, M.; Sabe, H.; Hanafusa, H.; Yi, T. Specific motifs recognized by the SH2 domains of Csk, 3BP2, fps/fes, GRB-2, HCP, SHC, Syk, and Vav. Mol. Cell. Biol. 1994, 14, 2777-2785.
40. Park, O. K.; Schaefer, L. K.; Wang, W.; Schaefer, T. S. Dimer stability as a determinant of differential DNA binding activity of Stat3 isoforms. J. Biol. Chem. 2000, 275, 32244-32249.
41. Turkson, J.; Ryan, D.; Kim, J. S.; Zhang, Y.; Chen, Z.; Haura, E.; Laudano, A.; Sebti, S.; Hamilton, A. D.; Jove, R. Phosphotyrosyl peptides block Stat3-mediated DNA-binding activity, gene regulation and cell transformation. J. Biol. Chem. 2001, 276, 45443-45455.
42. Ren, Z.; Cabell, L. A.; Schaefer, T. S.; McMurray, J. S. Identification of a high affinity phosphopeptide inhibitor of Stat3. Bioorg. Med. Chem. Lett. 2003, 13, 633-636.
43. Shao, H.; Cheng, H. Y.; Cook, R. G.; Tweardy, D. J. Identification and characterization of signal transducer and activator of transcription 3 recruitment sites within the epidermal growth factor receptor. Cancer Res. 2003, 63, 3923-3930.
44. Waksman, G.; Schoelson, S. E.; Pant, N.; Cowburn, D.; Kuriyan, J. Binding of a high affinity phosphotyrosyl peptide to the Src SH2 domain: crystal structures of the complexed and peptide free forms. Cell 1993, 72, 779-790.
45. Becker, S.; Gromer, B.; Muller, C. W. Three-dimensional structure of the Stat3β homodimer bound to DNA. Nature 1998, 394, 145-151.
46. (a) Xu, R. X.; Word, J. M.; Davis, D. G.; Rink, M. J.; Willard, D. H., Jr.; Gampe, R. T., Jr. Solution structure of the human pp60c-src SH2 domain complexed with a phosphorylated tyrosine pentapeptide. Biochemistry 1995, 34, 2107-2121.
47. (b) Plumme, R M. S.; Holland, D. R.; Shahripour, A.; Lunney, E. A.; Fergus, J. H.; Marks, J. S.; McConnell, P.; Mueller, W. T.; Sawyer, T. K. Design, synthesis, and cocrystal structure of a nonpeptide Src SH2 domain ligand. J. Med. Chem. 1997, 40, 3719-3725.
48. (c) Ettmayer, P.; France, D.; Gounarides, J.; Jarosinski, M.; Martin, M. S.; Rondeau, J. M.; Sabio, M.; Topiol, S.; Weidmann, B.; Zurini, M.; Bair, K. W. Structural and conformational requirements for high-affinity binding to the SH2 domain of Grb2. J. Med. Chem. 1999, 42, 971-980
49. (d) Tong, L.; Warren, T. C.; King, J.; Betageri, R.; Rose, J.; Jakes, S. Crystal structures of the human p561ck SH2 domain in complex with two short phosphotyrosyl peptides at 1.0 A and 1.8 A resolution. J. Mol. Biol. 1996, 256, 601-610.
50. (e) Breeze, A. L.; Kara, B. V.; Barratt, D. G.; Anderson, M.; Smith, J. C.; Luke, R. W.; Best, J. R.; Cartlidge, S. A. Structure of a specific peptide complex of the carboxyterminal SH2 domain from the p85 alpha subunit of phosphatidylinositol 3-kinase. EMBO J. 1996, 15, 3579-89.
51. (f) Pauptit, R. A.; Dennis, C. A.; Derbyshire, D. J.; Breeze, A. L.; Weston, S. A.; Rowsell, S.; Murshudov, G. N. NMR trial models: experiences with the colicin immunity protein Im7 and the p85alpha C-terminal SH2-peptide complex. Acta Crystallogr., Sect. D 2001, 57 (Part 10), 1397-1404.
52. (a) Chen, X.; Vinkemeier, U.; Zhao, Y.; Jeruzalmi, D.; Darnell, J. E.; Kuriyan, J. Crystal structure of a tyrosine phosphorylated STAT-1 dimer bound to DNA. Cell 1998, 93, 827-839.
53. (b) Mao, X.; Ren, Z.; Parker, G. N.; Sondermann, H.; Pastorello, M. A.; Wang, W.; McMurray, J. S.; Demeler, B.; Darnell, J. E., Jr.; Chen, X. Structural bases of unphosphorylated STAT1 association and receptor binding. Mol. Cell 2005, 17, 761-771.
54. Parts of this work were published in a preliminary communication: Ren, Z.; Coleman, D. R.; Cabell, L. A.; McMurray, J. S. The Development of Peptide-Based Inhibitors of Stat3α. In Peptide Revolution: Genomics, Proteomics & Therapeutics, Proceedings of the 18th American Peptide Symposium; Chorev, M., Sawyer, T. K., Eds.; American Peptide Society: San Diego, CA; 2004, pp 550-552.
55. Ottinger, E. A.; Shekels, L. L.; Bernlohr, D. A.; Barany, G. Synthesis of phosphotyrosine-containing peptides and their use as substrates for protein tyrosine phosphatases. Biochemistry 1993, 32, 4354-4361.
56. Pearson, D. A.; Blanchette, M.; Baker, M. L.; Guindon, C. A Trialkylsilanes as scavengers for the trifluoroacetic acid deblocking of protecting groups in peptide synthesis. Tetrahedron Lett. 1989, 30, 2739-2742.
57. Kates, S. A.; Daniels, S. B.; Albericio, F. Automated allyl cleavage for continuous-flow synthesis of cyclic and branched peptides. Anal. Biochem. 1993, 212, 303-310.
58. Chao, H.-G.; Bernatowicz, M. S.; Reiss, P. D.; Matsueda, G. R. Synthesis and application of bis-silylethyl-derived phosphateprotected Fmoc-phosphotyrosine derivatives for peptide synthesis. J. Org. Chem. 1994, 59, 6687-6691.
59. (a) Chao, H.-G.; Leiting, B.; Reiss, P. D.; Burkhardt, A. L.; Klimas, C. E.; Bolen, J. B.; Matseuda, G. R. Synthesis and Application of Fmoc-O-[bis(dimethylamino)phosphono]tyrosine, a versatile protected phosphotyrosine equivalent. J. Org. Chem. 1995, 60, 7710-7711.
60. (b) Ueki, M.; Tachibana, J.; Ishii, Y.; Okumura, J.; Goto, M. N,N′-Dialkyldiamide-type phosphate protecting groups for Fmoc synthesis of phosphotyrosine-containing peptides. Tetrahedron Lett. 1996, 37, 4953-4956.
61. (c) Ueki, M.; Goto, M.; Okumura, J.; Ishii, Y. N,N′-Dialkyldiamide- type phosphate protecting groups for Fmoc synthesis of phosphotyrosine- containing peptides: Optimization of the alkyl group. Bull. Chem. Soc. Jpn. 1998, 71, 1887-1898.
62. Chan, W. C.; Bycroft, B. W.; Evans, D. J.; White, P. D. A novel 4-aminobenzyl ester-based carboxy-protecting group for synthesis of atypical peptides by Fmoc-But solid-phase chemistry. J. Chem. Soc., Chem. Commun. 1995, 21, 2209-2210.
63. Haan, S.; Hemmann, U.; Hassiepen, U.; Schaper, F.; Schneider-Mergener, J.; Wollmer, A.; Heinrich, P. C.; Grotzinger, J. Characterization and binding specificity of the monomeric STAT3-SH2 domain. J. Biol. Chem. 1999, 274, 1342-1348.
64. (a) Lynch, B. A.; Loiacono, K. A.; Tiong, C. L.; Adams, S. E.; MacNeil, I. A. A fluorescence polarization based Src-SH2 binding assay. Anal. Biochem. 1997, 247, 77-82.
65. (b) Wu, P.; Brasseur, M.; Schindler, U. A high-throughput STAT binding assay using fluorescence polarization. Anal. Biochem. 1997, 249, 29-36.
66. (c) Schust, J.; Berg, T. A high-throughput fluorescence polarization assay for signal transducer and activator of transcription 3. Anal. Biochem. 2004, 330, 114-118.
67. Turkson, J.; Kim, J. S.; Zhang, S.; Yuan, J.; Huang, M.; Glenn, M.; Haura, E.; Sebti, S.; Hamilton, A. D.; Jove, R. Novel peptidomimetic inhibitors of signal transducer and activator of transcription 3 dimerization and biological activity. Mol. Cancer Ther. 2004, 3, 261-269.
68. Goodman, M.; Ro, S. Peptidomimetics for Drug Design. In Burger's Medicinal Chemistry and Drug Discovery, 5th ed.; Wolff, M. E., Ed.; John Wiley & Sons Inc.: New York, 1995; pp 803-861.
69. 2. J. Med. Chem. 1998, 41, 1741-1744.
70. (a) Chakraborty, A.; Dyer, K. F.; Cascio, M.; Mietzner, T. A.; Tweardy, D. J. Identification of a novel Stat3 recruitment and activation motif within the granulocyte colony-stimulating factor receptor. Blood 1999, 93, 15-24.
71. (b) Weber-Nordt, R. M.; Riley, J. K.; Greenlund, A. C.; Moore, K. W.; Darnell, J. E.; Schreiber, B. D. Stat-3 recruitment by two distinct ligand-induced, tyrosinephosphorylated docking sites in the interleukin-10 receptor intracellular domain. J. Biol. Chem. 1996a, 271, 27954-27961.
72. (c) Coffer, P.; Kruijer, W. EGF receptor deletions define a region specifically mediating STAT transcription factor activation. Biochem. Biophys. Res. Commun. 1995, 210, 74-81.
73. Wiederkehr-Adam, M.; Ernst, P.; Muller, K.; Bieck, E.; Gombert, F. O.; Ottl, J.; Graff, P.; Grossmuller, F.; Heim, M. H. Characterization of phosphopeptide motifs specific for the Src homology 2 domains of signal transducer and activator of transcription 1 (STAT1) and STAT3. J. Biol. Chem. 2003, 278, 16117-16128.
74. Bradshaw, J. M.; Waksman, G. Calorimetric investigation of proton linkage by monitoring both the enthalpy and association constant of binding: application to the interaction of the Src SH2 domain with a high-affinity tyrosyl phosphopeptide. Biochemistry 1998, 37, 15400-15407.
75. Arshady, R.; Atherton, E.; Clive, D. L. J.; Sheppard, R. C. Peptide synthesis. Part 1. Preparation and use of polar supports based on polydimethylacrylamide. J. Chem. Soc., Perkin Trans, 1 1981, 529-537.
76. DeLano, W. L. The PyMOL Molecular Graphics System; DeLano Scientific LLC: San Carlos, CA; http://www.pymol.org.